{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:51Z","timestamp":1787028651692,"version":"build-2736575974"},"reference-count":186,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis, and primary myelofibrosis are a unique group of clonal hematopoietic stem cell neoplasms that share somatic, gain-in-function driver mutations in JAK2, CALR, and MPL. As a consequence, these disorders exhibit similar phenotypic features, the most common of which are the ceaseless production of normal erythrocytes, myeloid cells, platelets alone or in combination, extramedullary hematopoiesis, myelofibrosis, and a potential for leukemic transformation. In the case of polycythemia vera and essential thrombocytosis, however, prolonged survival is possible. With an incidence value in the range of 0.5\u20132.0\/100,000, myeloproliferative neoplasms are rare disorders, but they are not new disorders, and after a century of scrutiny, their clinical features and natural histories are well-defined, though their individual management continues to be controversial. With respect to polycythemia vera, there has been a long-standing dispute between those who believe that the suppression of red blood cell production by chemotherapy is superior to phlebotomy to prevent thrombosis, and those who do not. With respect to essential thrombocytosis, there is a similar dispute about the role of platelets in veinous thrombosis, and the role of chemotherapy in preventing thrombosis by suppressing platelet production. Linked to these disputes is another: whether therapy with hydroxyurea promotes acute leukemia in disorders with a substantial possibility of longevity. The 21st century revealed new insights into myeloproliferative neoplasms with the discovery of their three somatic, gain-of-function driver mutations. Almost immediately, this triggered changes in the diagnostic criteria for myeloproliferative neoplasms and their therapy. Most of these changes, however, conflicted with prior well-validated, phenotypically driven diagnostic criteria and the management of these disorders. The aim of this review is to examine these conflicts and demonstrate how genomic discoveries in myeloproliferative neoplasms can be used to effectively complement the known phenotypic features of these disorders for their diagnosis and management.<\/jats:p>","DOI":"10.3390\/jcm13226957","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T10:44:37Z","timestamp":1732013077000},"page":"6957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myeloproliferative Neoplasms: Challenging Dogma"],"prefix":"10.3390","volume":"13","author":[{"given":"Jerry L.","family":"Spivak","sequence":"first","affiliation":[{"name":"Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: Reciprocity between quantitative JAK2 V617F and Mpl expression","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis","volume":"35","author":"Williams","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104127","DOI":"10.1016\/j.exphem.2023.10.005","article-title":"Germline MPL mutations may be a rare cause of \u201ctriple-negative\u201d thrombocytosis","volume":"129","author":"Borsani","year":"2024","journal-title":"Exp. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2013.08.007","article-title":"Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells","volume":"154","author":"Yamamoto","year":"2013","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.stem.2018.03.013","article-title":"Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment","volume":"22","author":"Yamamoto","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12495","article-title":"Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy","volume":"502","author":"Macaulay","year":"2013","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V90.2.597","article-title":"Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor","volume":"90","author":"Shimoda","year":"1997","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/0003-4819-152-5-201003020-00008","article-title":"Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation","volume":"152","author":"Spivak","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1126\/science.aat7873","article-title":"Changing concepts in hematopoietic stem cells","volume":"362","author":"Yamamoto","year":"2018","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.3707","article-title":"Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion","volume":"20","author":"Bruns","year":"2014","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1152\/jappl.1970.28.6.775","article-title":"Simultaneous measurement of plasma volume and cell mass in polycythemia of high altitude","volume":"28","author":"Sanchez","year":"1970","journal-title":"J. Appl. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9343(96)00351-8","article-title":"Inapparent polycythemia vera: An unrecognized diagnosis","volume":"102","author":"Lamy","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Krecak, I., Lekovic, D., Bogdanovic, A., and Lucijanic, M. (2024). High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera. Leuk. Lymphoma, 1\u20135.","DOI":"10.1080\/10428194.2024.2368639"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1172\/JCI102643","article-title":"The use of K42 or P32 labeled erythrocytes and I131 tagged human serum albumin in simultaneous blood volume determinations","volume":"31","author":"Berson","year":"1952","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1172\/JCI101772","article-title":"The distribution of red cells and plasma in large and minute vessels of the normal dog, determined by radioactive isotopes of iron and iodine","volume":"25","author":"Gibson","year":"1946","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V33.5.649.649","article-title":"Erythrocyte volume, plasma volume, and lean body mass in adult men and women","volume":"33","author":"Retzlaff","year":"1969","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0609.1984.tb02212.x","article-title":"Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values","volume":"33","author":"Pearson","year":"1984","journal-title":"Scand. J. Haematol."},{"key":"ref_24","first-page":"419","article-title":"Myeloproliferative disorders: Usefulness of X-linked probes in diagnosis","volume":"3","author":"Taylor","year":"1989","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_26","first-page":"85","article-title":"Polycythaemia vera, Erythrocytosis and Erythraemia","volume":"2","year":"1908","journal-title":"Q. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.1977.03280230055022","article-title":"Microcytic polycythemia. Frequency of nonthalassemic causes","volume":"238","author":"Bessman","year":"1977","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood.V20.2.173.173","article-title":"The natural history of iron deficiency induced by phlebotomy","volume":"20","author":"Conrad","year":"1962","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1172\/JCI102339","article-title":"Iron metabolism; hematopoiesis following phlebotomy; iron as a limiting factor","volume":"29","author":"Finch","year":"1950","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jmg.2006.048371","article-title":"Gain-of-function gene mutations and venous thromboembolism: Distinct roles in different clinical settings","volume":"44","author":"Colaizzo","year":"2007","journal-title":"J. Med. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: Myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2141.2005.05517.x","article-title":"An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia","volume":"129","author":"Johansson","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3324\/haematol.2018.213108","article-title":"Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: Limitations of erythrocyte values","volume":"104","author":"Silver","year":"2019","journal-title":"Haematologica"},{"key":"ref_36","first-page":"339","article-title":"Diagnosis and classification of the polycythemias","volume":"12","author":"Berlin","year":"1975","journal-title":"Semin. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","article-title":"Erythrocytosis in the general population: Clinical characteristics and association with clonal hematopoiesis","volume":"4","author":"Wouters","year":"2020","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.V75.8.1633.1633","article-title":"Essential thrombocythemia in two sisters originating from different stem cell levels","volume":"75","author":"Janssen","year":"1990","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2018.215582","article-title":"Masked polycythemia vera: Analysis of a single center cohort of 2480 red cell masses","volume":"105","author":"Maslah","year":"2020","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"ref_41","first-page":"144","article-title":"Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies","volume":"23","author":"Ellis","year":"1986","journal-title":"Semin. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: Myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2141.2002.03386.x","article-title":"Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia","volume":"117","author":"Messinezy","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjh.17848","article-title":"Revisiting Diagnostic performances of serum erythropoietin level and JAK2 mutation for polycythemias: Analysis of a cohort of 1090 patients with red cell mass measurement","volume":"196","author":"Maslah","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.7326\/0003-4819-139-6-200309160-00009","article-title":"The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis","volume":"139","author":"Ruggeri","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/s41375-021-01254-w","article-title":"Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?","volume":"35","author":"Spivak","year":"2021","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.1950.02910290018005","article-title":"Physiopathology and course of polycythemia vera as related to therapy","volume":"142","author":"Dameshek","year":"1950","journal-title":"J. Am. Med. Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.0954-6820.1950.tb10111.x","article-title":"Polycythaemia vera. Course and prognosis","volume":"138","author":"Videbaek","year":"1950","journal-title":"Acta Medica Scand."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","article-title":"Complications and causes of death in polycythaemia vera","volume":"172","author":"Chievitz","year":"1962","journal-title":"Acta Medica Scand."},{"key":"ref_52","first-page":"499","article-title":"Polycythaemia Vera: Clinical Studies on a Series of 127 Patients Managed without Radiation Therapy","volume":"33","author":"Perkins","year":"1964","journal-title":"Q. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tefferi, A., Guglielmelli, P., Larson, D.R., Finke, C., Wassie, E.A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A.A., and Lasho, T.L. (2014). Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 124.","DOI":"10.1182\/blood-2014-05-579136"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","article-title":"Normal life expectancy for polycythemia vera (PV) patients is possible","volume":"36","author":"Silver","year":"2022","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archinte.1938.00180170003001","article-title":"Course of polycythemia vera","volume":"62","author":"Rosenthal","year":"1938","journal-title":"Arch. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood.2019003869","article-title":"Clonal hematopoiesis sees Twin Peaks","volume":"135","author":"Shlush","year":"2020","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: When genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ajh.27013","article-title":"Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms","volume":"98","author":"Calabresi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/10428194.2022.2070914","article-title":"Excess mortality in younger patients with myeloproliferative neoplasms","volume":"64","author":"Saadeh","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2141.1987.00285.x","article-title":"Polycythaemia vera in young people: An analysis of 58 cases diagnosed before 40 years","volume":"67","author":"Najean","year":"1987","journal-title":"Br. J. Haematol."},{"key":"ref_65","first-page":"13","article-title":"Polycythemia vera in young patients: A study on the long-term risk of thrombosis, myelofibrosis and leukemia","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2018834044","article-title":"How I treat polycythemia vera","volume":"134","author":"Spivak","year":"2019","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.14798","article-title":"Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance","volume":"182","author":"Barraco","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","article-title":"Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: Results from the MYSEC project","volume":"8","author":"Barraco","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K","article-title":"Age and sex distributions of hematological malignancies in the U.K","volume":"15","author":"McNally","year":"1997","journal-title":"Hematol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms","volume":"28","author":"Escabi","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"306fs38","DOI":"10.1126\/scitranslmed.aac4428","article-title":"Aging as a driver of leukemogenesis","volume":"7","author":"McKerrell","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41467-018-02858-0","article-title":"Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential","volume":"9","author":"Wong","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00277-014-2205-y","article-title":"Polycythemia vera disease burden: Contributing factors, impact on quality of life, and emerging treatment options","volume":"93","author":"Stein","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1001\/jama.2010.853","article-title":"Primary myelofibrosis and the myeloproliferative neoplasms: The role of individual variation","volume":"303","author":"Stein","year":"2010","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2 V617F allele burden in polycythemia vera: Burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V94.8.2555.420k14_2555_2561","article-title":"Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera","volume":"94","author":"Moliterno","year":"1999","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2015-01-621110","article-title":"Molecular insights into regulation of JAK2 in myeloproliferative neoplasms","volume":"125","author":"Silvennoinen","year":"2015","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: A comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: A multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients","volume":"39","author":"Stein","year":"2011","journal-title":"Exp. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11444","DOI":"10.1073\/pnas.0404241101","article-title":"Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis","volume":"101","author":"Moliterno","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2010-06-290718","article-title":"Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis","volume":"116","author":"Posthuma","year":"2010","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","article-title":"Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants","volume":"133","author":"Pecquet","year":"2019","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/tra.12185","article-title":"Mpl traffics to the cell surface through conventional and unconventional routes","volume":"15","author":"Cleyrat","year":"2014","journal-title":"Traffic"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera","volume":"338","author":"Moliterno","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Albu, R.I., and Constantinescu, S.N. (2011). Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels. Front. Endocrinol., 2.","DOI":"10.3389\/fendo.2011.00071"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Spivak, J.L., Merchant, A., Williams, D.M., Rogers, O., Zhao, W., Duffield, A., Resar, L.S., Moliterno, A.R., and Zhao, Z.J. (2020). Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232801"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"key":"ref_102","first-page":"488","article-title":"The case for phlebotomy in polycythemia vera","volume":"32","author":"Dameshek","year":"1968","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41375-018-0199-5","article-title":"Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/bloodadvances.2019000822","article-title":"Response to meta-analysis of leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera","volume":"3","author":"Ronner","year":"2019","journal-title":"Blood Adv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00005792-198211000-00004","article-title":"Non-hematologic effects of chronic iron deficiency. A study of patients with polycythemia vera treated solely with venesections","volume":"61","author":"Rector","year":"1982","journal-title":"Medicine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-69-3-435","article-title":"Pagophagia and iron deficiency anemia","volume":"69","author":"Reynolds","year":"1968","journal-title":"Ann. Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1744-9987.1997.tb00028.x","article-title":"Advantages of isovolemic large-volume erythrocytapheresis as a rapidly effective and long-lasting treatment modality for red blood cell depletion in patients with polycythemia vera","volume":"1","author":"Kaboth","year":"1997","journal-title":"Ther. Apher."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Alvarez-Larran, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., P\u00e9rez-Andreu, V., Hern\u00e1ndez-Boluda, J.-C., Ayats, R., Salvador, C., Munta\u00f1ola, A., and Bellosillo, B. (2010). Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood, 116.","DOI":"10.1182\/blood-2010-01-263319"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia: A Systematic Review","volume":"167","author":"Chu","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients with Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa2308809","article-title":"Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera","volume":"390","author":"Kremyanskaya","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2007-04-086413","article-title":"Cell-cycle regulation by iron depletion","volume":"100","author":"Hershko","year":"2007","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000203745","article-title":"The relationship of polycythemia vera to leukemia; a critical review","volume":"4","author":"Schwartz","year":"1950","journal-title":"Acta Haematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood.V26.3.243.243","article-title":"Polycythemia Vera: Age Relationships and Survival","volume":"26","author":"Osgood","year":"1965","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00005792-196507000-00003","article-title":"Polycythemia Vera and Leukemia\u2014The Role of Radiation Treatment. A Study of 1222 Patients","volume":"44","author":"Modan","year":"1965","journal-title":"Medicine"},{"key":"ref_123","first-page":"206","article-title":"Wasserman and the history of polycythemia vera","volume":"62","author":"Berlin","year":"1995","journal-title":"Mt. Sinai J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.1971.tb02698.x","article-title":"The management of polycythaemia vera","volume":"21","author":"Wasserman","year":"1971","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"(1995). Polycythemia vera: The natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann. Intern. Med., 123, 656\u2013664.","DOI":"10.7326\/0003-4819-123-9-199511010-00003"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: A user\u2019s guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_127","first-page":"17","article-title":"From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: Pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V65.4.803.803","article-title":"Myelofibrosis with myeloid metaplasia: Pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly","volume":"65","author":"Wolf","year":"1985","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-007-0252-3","article-title":"Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis","volume":"86","author":"Hussein","year":"2007","journal-title":"Ann. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0609.1967.tb01647.x","article-title":"Polycythaemia vera and myelofibrosis","volume":"4","author":"Ikkala","year":"1967","journal-title":"Scand. J. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/pbc.22662","article-title":"Ghosal hematodiaphyseal dysplasia: A rare cause of a myelophthisic anemia","volume":"55","author":"Mazaheri","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1038\/bcj.2017.17","article-title":"Prognostic impact of bone marrow fibrosis in polycythemia vera: Validation of the IWG-MRT study and additional observations","volume":"7","author":"Barraco","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2011.047811","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Buhr","year":"2012","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.15562","article-title":"What is pre-fibrotic myelofibrosis and how should it be managed in 2018?","volume":"183","author":"Ianotto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14656566.2023.2203318","article-title":"Cytopenic myelofibrosis: Prevalence, relevance, and treatment","volume":"24","author":"Vachhani","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/hematology.2022000339","article-title":"Molecular prognostication in Ph-negative MPNs in 2022","volume":"2022","author":"Vannucchi","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/leu.2017.298","article-title":"Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2","volume":"32","author":"Bartels","year":"2018","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2018.04.012","article-title":"Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia","volume":"69","author":"Mora","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.leukres.2015.04.004","article-title":"Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis","volume":"39","author":"Gowin","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jha2.854","article-title":"Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis","volume":"5","author":"Oh","year":"2024","journal-title":"EJHaem"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Palandri, F., Al-Ali, H.K., Guglielmelli, P., Zuurman, M.W., Sarkar, R., and Gupta, V. (2023). Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. Cancers, 15.","DOI":"10.3390\/cancers15102859"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0007087419000049","article-title":"Life cycle of a star: Carl Sagan and the circulation of reputation","volume":"52","author":"Marsh","year":"2019","journal-title":"Br. J. Hist. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2015.07.650","article-title":"Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group","volume":"15","author":"Sirhan","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2023021503","article-title":"Moving toward disease modification in polycythemia vera","volume":"142","author":"Bewersdorf","year":"2023","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1073\/pnas.98.3.1036","article-title":"p53 accumulates but is functionally impaired when DNA synthesis is blocked","volume":"98","author":"Gottifredi","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: Susceptibility and incidence","volume":"92","author":"Leone","year":"2007","journal-title":"Haematologica"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/1097-0142(19880101)61:1<89::AID-CNCR2820610115>3.0.CO;2-0","article-title":"Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up","volume":"61","author":"Najean","year":"1988","journal-title":"Cancer"},{"key":"ref_160","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2017-07-746453","article-title":"Age-related clonal hematopoiesis","volume":"131","author":"Shlush","year":"2018","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428194.2015.1122785","article-title":"DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia","volume":"57","author":"Jain","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404591","article-title":"Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia","volume":"21","author":"Inami","year":"2007","journal-title":"Leukemia"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2007-07-103267","article-title":"Polycythemia vera following autologous transplantation for AML: Insights on the kinetics of JAK2V617F clonal dominance","volume":"110","author":"Antonioli","year":"2007","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41375-020-0849-2","article-title":"Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea","volume":"35","author":"Such","year":"2021","journal-title":"Leukemia"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Kerguelen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"17360","DOI":"10.1073\/pnas.1109272108","article-title":"Hydroxyurea induces de novo copy number variants in human cells","volume":"108","author":"Arlt","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e2404470121","DOI":"10.1073\/pnas.2404470121","article-title":"Revised mechanism of hydroxyurea-induced cell cycle arrest and an improved alternative","volume":"121","author":"Shaw","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004\u201315","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s12032-012-0190-3","article-title":"The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis","volume":"29","author":"Helbig","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.stem.2021.02.026","article-title":"Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms","volume":"28","author":"Tong","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41588-023-01638-x","article-title":"Inherited polygenic effects on common hematological traits influence clonal selection on JAK2(V617F) and the development of myeloproliferative neoplasms","volume":"56","author":"Guo","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Krichevsky","year":"2021","journal-title":"Leukemia"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"Rossi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2022-167719","article-title":"JAK inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms","volume":"140","author":"Maslah","year":"2022","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:34:53Z","timestamp":1760114093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":186,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226957"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226957","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}